{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T11:01:24Z","timestamp":1781262084982,"version":"3.54.1"},"reference-count":41,"publisher":"MDPI AG","issue":"12","license":[{"start":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T00:00:00Z","timestamp":1781222400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Background\/Objectives: There is limited data on treatment outcomes under immune checkpoint inhibitor (ICI) administration in solid organ transplant recipients (sOTRs). This study aims to evaluate cancer outcome and allograft rejection risk in sOTRs receiving ICI. Methods: This is a retrospective multicenter study. The data had been collected within the Swiss Transplant Cohort Study (STCS) database. We searched for matching individuals from May 2008 up to the end of 2024. The primary outcomes were treatment response and survival; the secondary outcome was allograft rejection. Additional analyses included associated factors such as tumor, transplant, and treatment characteristics. Results: We identified ten patients, six of whom received a kidney allograft, while the remaining four received a liver, lung, pancreas, or combined kidney\u2013pancreas transplant. Treatment response was achieved in half of the sOTRs, with a complete response (CR) in three and prolonged stable disease (SD) in two patients. CR was achieved in all three patients after only a few infusions. At the time of data analysis, four out of ten patients were still alive. Graft rejection occurred in six out of ten cases, five of which occurred after the first cycle of ICI administration. Conclusions: Data is limited and definitive conclusions from this study cannot be drawn given the limited sample size. However, ICI displays promising effects on cancer outcomes in sOTRs with advanced malignancies. The study\u2019s findings demonstrate an overall response in half of sOTRs, but with graft rejection occurring in a similar number of patients. We propose initiating immunotherapy as early as possible, given the promising results, particularly in patients with kidney transplants. We further suggest that in sOTRs, a few ICI infusions could potentially be a cautious option, pending further evidence.<\/jats:p>","DOI":"10.3390\/cancers18121918","type":"journal-article","created":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T09:49:51Z","timestamp":1781257791000},"page":"1918","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Cancer Treatment with Immune Checkpoint Inhibition in Solid Organ Transplant Recipients in Switzerland"],"prefix":"10.3390","volume":"18","author":[{"given":"Rahel","family":"Looser","sequence":"first","affiliation":[{"name":"Department of Dermatology, University Hospital Zurich, 8091 Zurich, Switzerland"},{"name":"Faculty of Medicine, University of Zurich, 8032 Zurich, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0542-7989","authenticated-orcid":false,"given":"G\u00fcnther F. L.","family":"Hofbauer","sequence":"additional","affiliation":[{"name":"Department of Dermatology, University Hospital Zurich, 8091 Zurich, Switzerland"},{"name":"Faculty of Medicine, University of Zurich, 8032 Zurich, Switzerland"},{"name":"allderm, Allergology and Dermatology, Guyer-Zeller-Strasse 10, 8620 Wetzikon, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5631-6096","authenticated-orcid":false,"given":"Dela","family":"Golshayan","sequence":"additional","affiliation":[{"name":"Transplantation Centre and Transplantation Immunopathology Laboratory, Department of Medicine, Lausanne University Hospital, University of Lausanne, 1011 Lausanne, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mirjam C.","family":"N\u00e4geli","sequence":"additional","affiliation":[{"name":"Department of Dermatology, University Hospital Zurich, 8091 Zurich, Switzerland"},{"name":"Faculty of Medicine, University of Zurich, 8032 Zurich, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"on behalf of the Swiss Transplant Cohort Study","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,6,12]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1177\/2050640618774631","article-title":"Use of checkpoint inhibitors in liver transplant recipients","volume":"6","author":"Munker","year":"2018","journal-title":"United Eur. Gastroenterol. J."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1001\/jama.2011.1592","article-title":"Spectrum of cancer risk among US solid organ transplant recipients","volume":"306","author":"Engels","year":"2011","journal-title":"JAMA"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"9595","DOI":"10.1002\/cam4.3525","article-title":"Cancer risk in heart or lung transplant recipients: A comprehensive analysis of 21 prospective cohorts","volume":"9","author":"Ge","year":"2020","journal-title":"Cancer Med."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1038\/s41581-018-0022-6","article-title":"Cancer in kidney transplant recipients","volume":"14","author":"Au","year":"2018","journal-title":"Nat. Rev. Nephrol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa2407417","article-title":"Final, 10-Year Outcomes with Nivolumab plus Ipilimumab in Advanced Melanoma","volume":"392","author":"Wolchok","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1056\/NEJMoa1805131","article-title":"PD-1 Blockade with Cemiplimab in Advanced Cutaneous Squamous-Cell Carcinoma","volume":"379","author":"Migden","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/S1470-2045(19)30728-4","article-title":"Cemiplimab in locally advanced cutaneous squamous cell carcinoma: Results from an open-label, phase 2, single-arm trial","volume":"21","author":"Migden","year":"2020","journal-title":"Lancet Oncol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/j.ccell.2015.03.001","article-title":"Immune checkpoint blockade: A common denominator approach to cancer therapy","volume":"27","author":"Topalian","year":"2015","journal-title":"Cancer Cell"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1634\/theoncologist.2014-0422","article-title":"The Evolving Role of Immune Checkpoint Inhibitors in Cancer Treatment","volume":"20","author":"Pennock","year":"2015","journal-title":"Oncologist"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.ctrv.2017.12.004","article-title":"Cancer immunotherapy in a neglected population: The current use and future of T-cell-mediated checkpoint inhibitors in organ transplant patients","volume":"63","author":"Chae","year":"2018","journal-title":"Cancer Treat. Rev."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1111\/imr.12523","article-title":"Advances in targeting co-inhibitory and co-stimulatory pathways in transplantation settings: The Yin to the Yang of cancer immunotherapy","volume":"276","author":"Kean","year":"2017","journal-title":"Immunol. Rev."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"e376","DOI":"10.1097\/TXD.0000000000000814","article-title":"Liver Allograft Failure After Nivolumab Treatment-A Case Report with Systematic Literature Research","volume":"4","author":"Gassmann","year":"2018","journal-title":"Transplant. Direct"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1634\/theoncologist.2019-0659","article-title":"The Safety and Efficacy of Checkpoint Inhibitors in Transplant Recipients: A Case Series and Systematic Review of Literature","volume":"25","author":"Kumar","year":"2020","journal-title":"Oncologist"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1200\/JCO.23.01498","article-title":"Cemiplimab for Kidney Transplant Recipients with Advanced Cutaneous Squamous Cell Carcinoma","volume":"42","author":"Hanna","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.kint.2020.12.015","article-title":"A multi-center study on safety and efficacy of immune checkpoint inhibitors in cancer patients with kidney transplant","volume":"100","author":"Murakami","year":"2021","journal-title":"Kidney Int."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1097\/CCO.0000000000000505","article-title":"Immune checkpoint blockade for organ transplant patients with advanced cancer: How far can we go?","volume":"31","author":"Ost","year":"2019","journal-title":"Curr. Opin. Oncol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1056\/NEJMc1509268","article-title":"Tumor Regression and Allograft Rejection after Administration of Anti-PD-1","volume":"374","author":"Lipson","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Goldman, J.W., Abdalla, B., Mendenhall, M.A., Sisk, A., Hunt, J., Danovitch, G.M., and Lum, E.L. (2018). PD 1 checkpoint inhibition in solid organ transplants: 2 sides of a coin\u2014Case report. BMC Nephrol., 19.","DOI":"10.1186\/s12882-018-1003-5"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1056\/NEJMoa1709030","article-title":"Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma","volume":"377","author":"Weber","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"e69","DOI":"10.1200\/JCO.2013.49.2314","article-title":"Successful administration of ipilimumab to two kidney transplantation patients with metastatic melanoma","volume":"32","author":"Lipson","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/s40425-015-0066-0","article-title":"Safety and efficacy of ipilimumab to treat advanced melanoma in the setting of liver transplantation","volume":"3","author":"Morales","year":"2015","journal-title":"J. Immunother. Cancer"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1001\/jamaoncol.2020.3381","article-title":"The Current Landscape of Immune Checkpoint Blockade in Hepatocellular Carcinoma: A Review","volume":"7","author":"Pinter","year":"2021","journal-title":"JAMA Oncol."},{"key":"ref_23","first-page":"331","article-title":"Excellent response to Anti-PD-1 therapy in a patient with hepatocellular carcinoma: Case report and review of literature","volume":"23","author":"Mamdani","year":"2017","journal-title":"Discov. Med."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"2492","DOI":"10.1016\/S0140-6736(17)31046-2","article-title":"Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): An open-label, non-comparative, phase 1\/2 dose escalation and expansion trial","volume":"389","author":"Sangro","year":"2017","journal-title":"Lancet"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/S1470-2045(21)00604-5","article-title":"Nivolumab versus sorafenib in advanced hepatocellular carcinoma (CheckMate 459): A randomised, multicentre, open-label, phase 3 trial","volume":"23","author":"Yau","year":"2022","journal-title":"Lancet Oncol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.21037\/jgo.2018.07.05","article-title":"Pilot evaluation of PD-1 inhibition in metastatic cancer patients with a history of liver transplantation: The Mayo Clinic experience","volume":"9","author":"DeLeon","year":"2018","journal-title":"J. Gastrointest. Oncol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1053\/j.gastro.2017.01.063","article-title":"Tapering of Immunosuppression and Sustained Treatment with Nivolumab in a Liver Transplant Recipient","volume":"152","author":"Gerbes","year":"2017","journal-title":"Gastroenterology"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1038\/ajg.2017.387","article-title":"Preserved Liver Transplant After PD-1 Pathway Inhibitor for Hepatocellular Carcinoma","volume":"112","author":"Varkaris","year":"2017","journal-title":"Am. J. Gastroenterol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"e26682","DOI":"10.1002\/pbc.26682","article-title":"Fatal orthotopic liver transplant organ rejection induced by a checkpoint inhibitor in two patients with refractory, metastatic hepatocellular carcinoma","volume":"64","author":"Friend","year":"2017","journal-title":"Pediatr. Blood Cancer"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"5181","DOI":"10.1002\/cam4.5394","article-title":"Allograft rejection following immune checkpoint inhibitors in solid organ transplant recipients: A safety analysis from a literature review and a pharmacovigilance system","volume":"12","author":"Cui","year":"2023","journal-title":"Cancer Med."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1947","DOI":"10.4049\/jimmunol.162.4.1947","article-title":"The role of CD80, CD86, and CTLA4 in alloimmune responses and the induction of long-term allograft survival","volume":"162","author":"Judge","year":"1999","journal-title":"J. Immunol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"2575","DOI":"10.1111\/j.1600-6143.2012.04224.x","article-title":"Role of the PD-1 pathway in the immune response","volume":"12","author":"Riella","year":"2012","journal-title":"Am. J. Transplant."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"S170","DOI":"10.1016\/j.jhep.2015.02.042","article-title":"From immunosuppression to tolerance","volume":"62","author":"Adams","year":"2015","journal-title":"J. Hepatol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1016\/S1470-2045(22)00368-0","article-title":"Immune checkpoint inhibitors in kidney transplant recipients: A multicentre, single-arm, phase 1 study","volume":"23","author":"Carroll","year":"2022","journal-title":"Lancet Oncol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"3018","DOI":"10.1111\/ajt.15480","article-title":"Two-year outcomes in de novo renal transplant recipients receiving everolimus-facilitated calcineurin inhibitor reduction regimen from the TRANSFORM study","volume":"19","author":"Berger","year":"2019","journal-title":"Am. J. Transplant."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"2872","DOI":"10.1200\/JCO.2018.79.0006","article-title":"Impact of Baseline Steroids on Efficacy of Programmed Cell Death-1 and Programmed Death-Ligand 1 Blockade in Patients with Non-Small-Cell Lung Cancer","volume":"36","author":"Arbour","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"10322","DOI":"10.3389\/ti.2022.10322","article-title":"An Analysis by the European Committee on Organ Transplantation of the Council of Europe Outlining the International Landscape of Donors and Recipients Sex in Solid Organ Transplantation","volume":"35","author":"Cozzi","year":"2022","journal-title":"Transpl. Int."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1097\/TP.0000000000004459","article-title":"Immune Checkpoint Inhibitors in Solid Organ Transplant Recipients with Advanced Skin Cancers-Emerging Strategies for Clinical Management","volume":"107","author":"Leiter","year":"2023","journal-title":"Transplantation"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1056\/NEJMoa2209813","article-title":"Neoadjuvant Cemiplimab for Stage II to IV Cutaneous Squamous-Cell Carcinoma","volume":"387","author":"Gross","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1016\/j.healun.2008.02.015","article-title":"Role for CD4+CD25+ T Cells in Inhibition of Graft Rejection by Extracorporeal Photopheresis","volume":"27","author":"George","year":"2008","journal-title":"J. Heart Lung Transplant."},{"key":"ref_41","doi-asserted-by":"crossref","unstructured":"Carreras, E., Dufour, C., Mohty, M., and Kr\u00f6ger, N. (2019). The EBMT Handbook: Hematopoietic Stem Cell Transplantation and Cellular Therapies, Springer.","DOI":"10.1007\/978-3-030-02278-5"}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/18\/12\/1918\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T10:30:49Z","timestamp":1781260249000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/18\/12\/1918"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,12]]},"references-count":41,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2026,6]]}},"alternative-id":["cancers18121918"],"URL":"https:\/\/doi.org\/10.3390\/cancers18121918","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,12]]}}}